ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer

Genes and Cancer

Volumn 2, Issue 8, 2011, Pages 792-804

  Mill, Christopher P ^a,b,f   Zordan, Michael D ^c,d   Rothenberg, S Michael ^e   Settleman, Jeffrey ^e,g   Leary, James F ^b,c,d,h   Riese II, David J ^a,b,d,f  

^a PURDUE UNIVERSITY   (United States)

^b Purdue University   (United States)

^c PURDUE UNIVERSITY   (United States)

^d PURDUE UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f AUBURN UNIVERSITY   (United States)

^g GENENTECH INC   (United States)

^h PURDUE UNIVERSITY   (United States)

Author keywords

breast cancer; crosstalk; ErbB2; ErbB4; invasiveness; motility

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; NEU DIFFERENTIATION FACTOR; NEU DIFFERENTIATION FACTOR 2B; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CELL ANCHORAGE; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ERBB4 GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

EID: 84858299509     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911431080     Document Type: Article

References (51)

1. Carpenter G.ErbB-4: mechanism of action and biology.Exp Cell Res. 2003;284:66-77.
2. Jones RB,Gordus A,Krall JA,MacBeath G.A quantitative protein interaction network for the ErbB receptors using protein microarrays.Nature. 2006;439:168-74.
3. Schulze WX,Deng L,Mann M.Phosphotyrosine interactome of the ErbB-receptor kinase family.Mol Syst Biol. 2005;1 2005:0008.
4. van der Geer P,Hunter T,Lindberg RA.Receptor protein-tyrosine kinases and their signal transduction pathways.Annu Rev Cell Biol. 1994;10:251-337.
5. Jones FE.HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.J Mammary Gland Biol Neoplasia. 2008;13:247-58.
6. Sundvall M,Iljin K,Kilpinen S, et al.Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia. 2008;13:259-68.
7. Saglam O,Shah V,Worsham MJ.Molecular differentiation of early and late stage laryngeal squamous cell carcinoma: an exploratory analysis.Diagn Mol Pathol. 2007;16:218-21.
8. Thybusch-Bernhardt A,Beckmann S,Juhl H.Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage.Int J Surg Investig. 2001;2:393-400.
9. Uberall I,Kolar Z,Trojanec R,Berkovcova J,Hajduch M.The status and role of ErbB receptors in human cancer.Exp Mol Pathol. 2008;84:79-89.
10. Ghayad SE,Vendrell JA,Larbi SB, et al.Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.Int J Cancer. 2010;126:545-62.
11. Naresh A,Long W,Vidal GA, et al.The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.Cancer Res. 2006;66:6412-20.
12. Gilmour LM,Macleod KG,McCaig A, et al.Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.Cancer Res. 2001;61:2169-76.
13. Lee CM,Shrieve DC,Zempolich KA, et al.Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.Gynecol Oncol. 2005;99:415-21.
14. Pitfield SE,Bryant I,Penington DJ,Park G,Riese DJ.Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines.Oncol Res. 2006;16:179-93.
15. Williams EE,Trout LJ,Gallo RM, et al.A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.Cancer Lett. 2003;192:67-74.
16. Mill CP,Gettinger KL,Riese DJ.Ligand stimulation of ErbB4 and A constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.Exp Cell Res. 2011;317:392-404.
17. Vidal GA,Clark DE,Marrero L,Jones FE.A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities.Oncogene. 2007;26:462-6.
18. Linggi B,Cheng QC,Rao AR,Carpenter G.The ErbB-4 s80 intracellular domain is a constitutively active tyrosine kinase.Oncogene. 2006;25:160-3.
19. Gilbertson RJ,Clifford SC,MacMeekin W, et al.Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma.Cancer Res. 1998;58:3932-41.
20. Burgess AW.EGFR family: structure physiology signalling and therapeutic targets.Growth Factors. 2008;26:263-74.
21. Abd El-Rehim DM,Pinder SE,Paish CE, et al.Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.Br J Cancer. 2004;91:1532-42.
22. Tang CK,Concepcion XZ,Milan M, et al.Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.Cancer Res. 1999;59:5315-22.
23. Prickett TD,Agrawal NS,Wei X, et al.Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.Nat Genet. 2009;41:1127-32.
24. Graus-Porta D,Beerli RR,Daly JM,Hynes NE.ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.EMBO J. 1997;16:1647-55.
25. Wang LM,Kuo A,Alimandi M, et al.ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4.Proc Natl Acad Sci U S A. 1998;95:6809-14.
26. Kruser TJ,Wheeler DL.Mechanisms of resistance to HER family targeting antibodies.Exp Cell Res. 2010;316:1083-100.
27. Jones KL,Buzdar AU.Evolving novel anti-HER2 strategies.Lancet Oncol. 2009;10:1179-87.
28. Riese DJ,van Raaij TM,Plowman GD,Andrews GC,Stern DF.The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.Mol Cell Biol. 1995;15:5770-6.
29. Gallo RM,Bryant I,Fry R,Williams EE,Riese DJ.Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.Biochem Biophys Res Commun. 2006;349:372-82.
30. Andersson U,Guo D,Malmer B, et al.Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas.Acta Neuropathol. 2004;108:135-42.
31. Honegger AM,Dull TJ,Felder S, et al.Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing.Cell. 1987;51:199-209.
32. Junttila TT,Sundvall M,Lundin M, et al.Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.Cancer Res. 2005;65:1384-93.
33. Red Brewer M,Choi SH,Alvarado D, et al.The juxtamembrane region of the EGF receptor functions as an activation domain.Mol Cell. 2009;34:641-51.
34. Feng SM,Sartor CI,Hunter D, et al.The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation.Mol Endocrinol. 2007;21:1861-76.
35. Muraoka-Cook RS,Sandahl M,Husted C, et al.The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells.Mol Biol Cell. 2006;17:4118-29.
36. Aqeilan RI,Donati V,Gaudio E, et al.Association of Wwox with ErbB4 in breast cancer.Cancer Res. 2007;67:9330-6.
37. Karamouzis MV,Badra FA,Papavassiliou AG.Breast cancer: the upgraded role of HER-3 and HER-4.Int J Biochem Cell Biol. 2007;39:851-6.
38. Tiseo M,Loprevite M,Ardizzoni A.Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.Curr Med Chem Anticancer Agents. 2004;4:139-48.
39. Albanell J,Codony J,Rovira A,Mellado B,Gascon P.Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.Adv Exp Med Biol. 2003;532:253-68.
40. Johnson BE,Janne PA.Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer.Clin Cancer Res. 2006;12:.
41. Rothenberg SM,Engelman JA,Le S, et al.Modeling oncogene addiction using RNA interference.Proc Natl Acad Sci U S A. 2008;105:12480-4.
42. Plowman GD,Culouscou JM,Whitney GS, et al.Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.Proc Natl Acad Sci U S A. 1993;90:1746-50.
43. Leptak C,Ramon Y,Cajal S,Kulke R, et al.Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16.J Virol. 1991;65:7078-83.
44. Riese DJ,DiMaio D.An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein.Oncogene. 1995;10:1431-9.
45. Wilson KJ,Mill CP,Cameron EM, et al.Inter-conversion of neuregulin2 full and partial agonists for ErbB4.Biochem Biophys Res Commun. 2007;364:351-7.
46. Mann R,Mulligan RC,Baltimore D.Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.Cell. 1983;33:153-9.
47. Miller AD,Buttimore C.Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.Mol Cell Biol. 1986;6:2895-902.
48. Penington DJ,Bryant I,Riese DJ.Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities.Cell Growth Differ. 2002;13:247-56.
49. Riese DJ,Komurasaki T,Plowman GD,Stern DF.Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2.J Biol Chem. 1998;273:11288-94.
50. Zordan MD,Mill CP,Riese DJ,Leary JF.A high throughput, interactive imaging, bright-field wound healing assay.Cytometry A. 2011;:227-32.
51. Hobbs SS,Cameron EM,Hammer RP, et al.Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase.Oncogene. 2004;23:883-93.